Dantrolene sodium improves the force-frequency relationship and β- adrenergic responsiveness in failing human myocardium

European Journal of Heart Failure

Volumn 1, Issue 2, 1999, Pages 177-186

  Meissner, Achim ^a   Min, Jiang Yong ^a   Haake, Nils ^a   Hirt, Stephan ^a   Simon, Rüdiger ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Dantrolene sodium; adrenergic responsiveness

Indexed keywords

CALCIUM; DANTROLENE; VERAPAMIL;

ADULT; ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLE; DRUG EFFECT; FEMALE; HEART CONTRACTION; HEART FAILURE; HUMAN; HUMAN TISSUE; MALE; MYOCARDIAL DISEASE; PRIORITY JOURNAL; SYSTOLE;

EID: 0033510664     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(99)00017-3     Document Type: Article

References (29)

1. Bristow M.R., Ginsburg R., Minobe W. et al. Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med. 307:1982;205-211.
2. Feldman M.D., Gwathmey J.K., Phillips P., Schoen F., Morgan J.P. Reversal of the force-frequency relationship in working myocardium from patients with end-stage heart failure. J Appl Cardiol. 3:1988;273-283.
3. Mulieri L.A., Hasenfuss G., Leavitt B., Allen P.D., Alpert N.R. Altered myocardial force-frequency relation in human heart failure. Circulation. 85:1992;1743-1750.
4. Morgan J.P., Erny R.E., Allen P.D., Grossman W., Gwathmey J.K. Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure. Circulation. 81(Suppl III):1990;III21-III32.
5. 2+ ATPase in failing and nonfailing human myocardium. Circ Res. 75:1994;434-442.
6. Pieske B., Kretschmann B., Meyer M. et al. Alterations of intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. Circulation. 92:1995;1169-1178.
7. Beuckelmann D.J., Nabauer M., Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation. 85:1992;1046-1055.
8. Gwathmey J.K., Slawsky M.T., Hajjar R.J., Briggs G.M., Morgan J.P. Role of intracellular calcium handling in force-interval relationships of human ventricular myocardium. J Clin Invest. 85:1990;1599-1613.
9. Ellis F.R., Heffron J.J. Clinical and biochemical aspects of malignant hyperthermia. Atkinson R.S., Adams A.P. Recent advances in anesthesia and analgesia. 1985;173-207 Churchill-Livingstone, New York, NY.
10. Huckell V.F., Staniloff H.M., Britt B.A., Waxman M.B., Morch J.E. Cardiac manifestations of malignant hyperthermia susceptibility. Circulation. 58:1978;916-925.
11. 2+ release from sarcoplasmic reticulum in guinea pig skeletal muscle. Eur J Pharmacol. 178:1990;11-19.
12. i measured in vivo in patients susceptible to malignant hyperthermia. Anesthesiology. 76:1992;711-719.
13. 2+ overloaded cardiac muscle. Eur J Pharmacol. 316:1996;333-342.
14. Mulieri L.A., Hasenfuss G., Ittleman F., Blanchard E.M., Alpert N.R. Protection of human left ventricular myocardium from cutting injury with 2,3-butanedione monoxime. Circ Res. 65:1989;1441-1444.
15. Kihara Y., Morgan J.P. A comparative study of the three methods for intracellular loading of the calcium indicator aequorin in ferret papillary muscles. Biochem Biophys Res Commun. 162:1989;402-407.
16. Blinks J.R. The use of photoproteins as calcium indicators in cellular physiology. Baker P.F. Techniques in cellular physiology, part III. 1982;126/1-126/38 Elsevier/North Holland Science, Shannon.
17. Gwathmey J.K., Warren S.E., Briggs G.M. et al. Diastolic dysfunction in hypertrophic cardio-myopathy. J Clin Invest. 87:1991;1023-1031.
18. Meyer M., Schillinger W., Pieske B. et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation. 92:1995;778-784.
19. Go O.L., Moschella M.C., Watras J., Handa K.K., Fyfe B.S., Marks A.R. Differential regulation of two types of intracellular calcium release channels during end-stage heart failure. J Clin Invest. 95:1995;888-894.
20. Lakatta E.G. Chaotic behaviour of myocardial cells: possible implications regarding the pathophysiology of heart failure. Perspect Biol Med. 32:1989;421-433.
21. Ward A., Caffmann M.O., Sorkin E.M. Dantrolene: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs. 32:1986;130-158.
22. White M.D., Collins J.G., Denborough M.A. The effect of dantrolene on skeletal muscle sarcoplasmic reticulum function in malignant hyperpyrexia in pigs. Biochem J. 212:1983;399-405.
23. Kentsch M., Roewer N., Kunze K.P., Kuck K.H. Intravenous dantrolene does not exhibit calcium channel blocking effects on the cardiac conduction system in humans. Anesthesiology. 75:1991;583-587.
24. Brocklehurst L. Dantrolene sodium in skinned muscle fibres. Nature. 254:1975;346.
25. Amende I., Bentivegna L., Zeind A.J., Wenzlaff P., Grossman W., Morgan J.P. Intracellular calcium and ventricular function. Effects of nisoldipine on global ischemia in the isovolumic coronary-perfused ferret heart. J Clin Invest. 89:1992;2060-2065.
26. Yusuf S. Calcium antagonists in coronary artery disease and hypertension: time for reevaluation? Circulation. 92:1995;1079-1082.
27. Honerjaeger P., Alischewski N. Inotropic and electrophysiological effects of dantrolene on guinea pig papillary muscle. Naunyn-Schmiederbergs Arch Pharmacol. 322:1983;237-244.
28. i by nonlinear indicators: a quantitative analysis. Biophys J. 48:1985;533-537.
29. 2+ concentrations in living cells. Prog Biophys Mol Biol. 40:1982;1-114.